BioNTech (BNTX) Soars: Stock Adds 5.2% in Session
BioNTech SE BNTX was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 31.2% in the past one-month time frame.
The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
BioNTech currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
BioNTech SE
BioNTech SE price | BioNTech SE Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Axcella Health Inc. AXLA, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
Axcella Health Inc. (AXLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
